☆ 4.5 Article

Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction

EUROPEAN JOURNAL OF HEART FAILURE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Cardiac & Cardiovascular Systems

Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets

Barry A. Borlaug et al.

Summary: Obesity and heart failure with preserved ejection fraction (HFpEF) are two intertwining epidemics, and obesity may have widespread effects on the cardiovascular system, leading to symptomatic HFpEF. Understanding the pathophysiological mechanisms of obese HFpEF is crucial for developing new therapeutic approaches.

CARDIOVASCULAR RESEARCH (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Comprehensive characterization of non-cardiac comorbidities in acute heart failure: an analysis of ESC-HFA EURObservational Research Programme Heart Failure Long-Term Registry

Ovidiu Chioncel et al.

Summary: This study investigates the prevalence and associations of non-cardiac comorbidities (NCCs) with in-hospital and post-discharge outcomes in acute heart failure (AHF) patients with different ejection fraction (EF) categories. Multiple NCCs are associated with poor outcomes, and the association between individual comorbidities and post-discharge outcomes varies among different EF categories, suggesting the need for specific multidisciplinary management programs for different comorbidities in post-discharge phase.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced

Joao Pedro Ferreira et al.

Summary: This study investigates the impact of empagliflozin on haematocrit and anaemia in patients with heart failure and reduced ejection fraction. It found that anaemia is associated with poor outcomes, and empagliflozin can reduce the risk of new-onset anaemia and improve heart failure and kidney outcomes, regardless of the baseline anaemia status.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study

Ridha I. S. Alnuwaysir et al.

Summary: Iron deficiency, chronic kidney disease, and/or anemia in patients with heart failure have significant overlap in biomarker profiles, indicating common pathways associated with these syndromes. Iron deficiency alone or on top of chronic kidney disease and anemia is associated with worse quality of life, exercise capacity, and prognosis in patients with worsening heart failure.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Chronic Obstructive Pulmonary Disease and Heart Failure: A Breathless Conspiracy

Pierpaolo Pellicori et al.

CARDIOLOGY CLINICS (2022)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Metabolic disorders as growing risk factors and comorbidities in heart failure

Luxiang Shang et al.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Twenty-year trends in heart failure among US adults, 1999-2018: The growing impact of obesity and diabetes

Stefano Ciardullo et al.

Summary: Over the past 20 years, the prevalence of HF in US adults has remained stable, while the prevalence of obesity and diabetes has increased, affecting half of patients with HF. There have been improvements in the control of dyslipidemia and, to a lesser extent, blood pressure, but there is still a significant gap in the guideline-directed use of HF and diabetes medications.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF

Kieran F. Docherty et al.

Summary: This study examined the prevalence and consequences of iron deficiency in heart failure patients and found that it was associated with worse outcomes. Dapagliflozin had an effect on markers of iron metabolism and improved outcomes regardless of iron status at baseline.

CIRCULATION (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Dapagliflozin for heart failure according to body mass index: the DELIVER trial

Carly Adamson et al.

Summary: Obesity is common in HFpEF patients and is associated with higher rates of heart failure hospitalization and worse health status. Treatment with dapagliflozin improves cardiovascular outcomes across the spectrum of BMI, leads to greater symptom improvement in patients with obesity, compared with those without, and has the additional benefit of causing modest weight loss.

EUROPEAN HEART JOURNAL (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF

Pooja Dewan et al.

Summary: In patients with heart failure with reduced ejection fraction, approximately one in eight individuals also had chronic obstructive pulmonary disease. Patients with COPD had a higher risk of adverse outcomes, but the efficacy of dapagliflozin was consistent in patients with and without COPD.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial

Jawad H. Butt et al.

Summary: The study showed that in HFrEF patients, dapagliflozin significantly reduced NT-proBNP levels after 8 months of treatment compared to placebo. Additionally, dapagliflozin reduced the risk of worsening HF and death, and improved symptoms across the spectrum of baseline NT-proBNP levels included in DAPA-HF.

CIRCULATION-HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis

Luis E. Rohde et al.

Summary: This study assessed the relative contribution of cardiac, comorbid, and demographic factors in heart failure patients and how they influence the prognosis and treatment efficacy of sacubitril/valsartan. The results show that disease burden domains play a significant role in determining the therapeutic benefits of sacubitril/valsartan across different ranges of left ventricular ejection fraction.

CIRCULATION-HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF

Solmaz Ehteshami-Afshar et al.

Summary: COPD is a common comorbidity in heart failure with reduced ejection fraction, associated with worse outcomes, but sacubitril/valsartan remains beneficial in this high-risk subgroup.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The effect of three major co-morbidities on quality of life and outcome of patients with heart failure with reduced ejection fraction

Jan Benes et al.

Summary: In patients with stable advanced HFrEF, co-morbidities such as diabetes, chronic obstructive pulmonary disease, and chronic kidney disease do not directly impact quality of life but negatively affect prognosis through lower levels of HF pharmacotherapy and increased myocardial stress and injury.

ESC HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF

Leanne Mooney et al.

Summary: Approximately 1 in 7 patients with heart failure with preserved ejection fraction had concomitant COPD, which was associated with greater functional limitation and a higher risk of heart failure hospitalization and death.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Common Comorbidities that Alter Heart Failure Prognosis-Shaping New Thinking for Practice

Pupalan Iyngkaran et al.

Summary: At least half of heart failure patients have comorbidities that may be undertreated, leading to increased risk of complications and readmissions. The current community practice structure segregates primary, speciality, and allied health care, which may impede effective communication and management. Specialty training in cardiology produces excellent sub-specialists, but this has led to alienation from general cardiology and primary care providers.

CURRENT CARDIOLOGY REVIEWS (2021)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Patient-reported outcomes for heart failure with preserved ejection fraction: conducting quality studies on quality of life

Muhammad Shahzeb Khan et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF

Ankeet S. Bhatt et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Trends in prevalence of comorbidities in heart failure clinical trials

Muhammad Shahzeb Khan et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care JACC State-of-the-Art Review

John A. Spertus et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Patient-Reported Outcomes The Future of Heart Failure Care

Paul A. Heidenreich

JACC-HEART FAILURE (2019)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction Rationale and Design of the PARAGON-HF Trial

Scott D. Solomon et al.

JACC-HEART FAILURE (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Health-Related Quality of Life Outcomes in PARADIGM-HF

Eldrin F. Lewis et al.

CIRCULATION-HEART FAILURE (2017)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials

Ewa A. Jankowska et al.

EUROPEAN JOURNAL OF HEART FAILURE (2016)

添加到收藏夹

Article Medicine, General & Internal

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure

John J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Non-cardiovascular comorbidity, severity and prognosis in non-selected heart failure populations: A systematic review and meta-analysis

C. A. Rushton et al.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial

Marc A. Pfeffer et al.

CIRCULATION (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey

Vincent M. van Deursen et al.

EUROPEAN JOURNAL OF HEART FAILURE (2014)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction

Robert J. Mentz et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure

John J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population With Heart Failure and Preserved Versus Reduced Ejection Fraction

Sameer Ather et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction

Akshay S. Desai et al.

AMERICAN HEART JOURNAL (2011)

添加到收藏夹

Article

The Persistent Exclusion of Older Patients From Ongoing Clinical Trials Regarding Heart Failure

Antonio Cherubini et al.

ARCHIVES OF INTERNAL MEDICINE (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.